Literature DB >> 30089564

Early Versus Late Referral for Catheter Ablation of Ventricular Tachycardia in Patients With Structural Heart Disease: A Systematic Review and Meta-Analysis of Clinical Outcomes.

Jorge Romero1, Luigi Di Biase1, Juan Carlos Diaz1, Renato Quispe1, Xianfeng Du2, David Briceno1, Ricardo Avendano1, Usha Tedrow3, Roy M John4, Gregory F Michaud4, Andrea Natale1, William G Stevenson5, Saurabh Kumar6.   

Abstract

OBJECTIVES: This was a meta-analysis of published studies to examine the impact of early referral on outcomes after catheter ablation for ventricular tachycardia (VT) in patients with structural heart disease.
BACKGROUND: Patients are frequently referred for VT ablation after failure of antiarrhythmic drugs to control VT. Some studies have suggested that early referral might confer better outcomes.
METHODS: An electronic search was performed using major databases. The primary outcomes were long-term VT recurrence and total mortality. Secondary outcomes were acute procedural success and acute complications.
RESULTS: Three studies were included with a total of 980 patients (mean age 64 ± 12 years, 71% males). Mean follow-up was 29 ± 27 months. Early referral for VT ablation was associated with decreased VT recurrence and acute complications compared with late referral (relative risk: 0.69 [95% confidence interval: 0.58 to 0.82], p < 0.0001 and relative risk: 0.50 [95% confidence interval: 0.27 to 0.93], p = 0.03, respectively). There was no significant difference between early and late referral for total mortality and acute success.
CONCLUSIONS: Late referral for VT ablation was associated with worse outcomes (VT recurrence and acute complications) in patients with structural heart disease, which suggests that early referral for VT ablation might be a reasonable consideration in this patient population.
Copyright © 2018 American College of Cardiology Foundation. All rights reserved.

Entities:  

Keywords:  VT recurrence; acute complications; antiarrhythmic drugs; catheter ablation; early referral; ischemic cardiomyopathy; mortality; nonischemic cardiomyopathy; ventricular tachycardia

Mesh:

Year:  2018        PMID: 30089564     DOI: 10.1016/j.jacep.2017.12.008

Source DB:  PubMed          Journal:  JACC Clin Electrophysiol        ISSN: 2405-500X


  6 in total

Review 1.  Neuromodulation Approaches for Cardiac Arrhythmias: Recent Advances.

Authors:  Veronica Dusi; Ching Zhu; Olujimi A Ajijola
Journal:  Curr Cardiol Rep       Date:  2019-03-18       Impact factor: 2.931

Review 2.  Prophylactic catheter ablation of ventricular tachycardia in ischemic cardiomyopathy: a systematic review and meta-analysis of randomized controlled trials.

Authors:  Varunsiri Atti; Venkat Vuddanda; Mohit K Turagam; Praveen Vemula; Zubair Shah; Himakar Nagam; Srikanth Yandrapalli; Mohammad-Ali Jazayeri; Scott Koerber; Juan Viles Gonzalez; Andrea Natale; Luigi Di Biase; Dhanunjaya R Lakkireddy
Journal:  J Interv Card Electrophysiol       Date:  2018-04-21       Impact factor: 1.900

Review 3.  Contemporary Management of Complex Ventricular Arrhythmias.

Authors:  Benedict M Wiles; Anthony C Li; Michael C Waight; Magdi M Saba
Journal:  Arrhythm Electrophysiol Rev       Date:  2022-04

Review 4.  Optimal Timing of VT Ablation for Patients with ICD Therapies.

Authors:  Andrea Radinovic; Francesca Baratto; Paolo Della Bella
Journal:  Curr Cardiol Rep       Date:  2020-07-09       Impact factor: 2.931

Review 5.  Catheter Ablation of Ventricular Tachycardia in Arrhythmogenic Right Ventricular Dysplasia/Cardiomyopathy.

Authors:  Fa Po Chung; Chin Yu Lin; Yenn Jiang Lin; Shih Lin Chang; Li Wei Lo; Yu Feng Hu; Ta Chuan Tuan; Tze Fan Chao; Jo Nan Liao; Ting Yung Chang; Shih Ann Chen
Journal:  Korean Circ J       Date:  2018-10       Impact factor: 3.243

6.  Ablation of ventricular tachycardia in 2021.

Authors:  Stefano Bianchi; Filippo Maria Cauti
Journal:  Eur Heart J Suppl       Date:  2021-10-08       Impact factor: 1.803

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.